招募时确诊性多参数磁共振成像可延长主动监测的持续时间并降低随访时的升级率
这项回顾性单中心研究纳入两个主动监测队列(206例和310例),后者在招募时接受mpMRI和靶向活检。结果显示,招募时行mpMRI±靶向活检者的无进展生存率和无活检升级生存率更高,但两组在根治性前列腺切除术后显著癌的检出率无显著差异。
要点
- 招募时确诊性mpMRI±靶向活检与主动监测期间更高的无进展生存率相关(HR 0.3,95%CI 0.2-0.5)。
- 招募时mpMRI±靶向活检与更高的无活检升级生存率相关(HR 0.3,95%CI 0.2-0.6)。
- 两组在根治性前列腺切除术后显著癌检出率无显著差异(22% vs 28%,p=0.47)。
核心结论
- 招募时确诊性mpMRI±靶向活检与主动监测期间更高的无进展生存率和无活检升级生存率相关。
- 但相当比例的患者在转为主动治疗后出现显著癌。
研究设计与样本
- 回顾性单中心研究,纳入两个主动监测队列,分别为206例和310例患者。
- 后一组在招募时接受mpMRI和靶向活检。
- 采用Kaplan-Meier曲线量化无进展生存率和无活检升级生存率,Cox回归分析独立预测因素,Logistic回归预测根治性前列腺切除术后显著癌。
主要发现
- 中位随访时间和主动监测中位持续时间为46(24-70)个月和36(23-58)个月。
- 招募时行mpMRI者在1年、3年和5年无进展生存率分别为98%、80%和70%,对照组分别为91%、57%和35%(所有p<0.01)。
- Cox回归分析显示,招募时确诊性mpMRI±靶向活检是无进展生存率的独立预测因素(HR 0.3;95%CI 0.2-0.5;p<0.01)。
- 两组因任何原因和活检原因终止主动监测的人数分别为50例(16%)vs 128例(62%)和26例(8.5%)vs 64例(31%)(所有p<0.01)。
- 招募时行mpMRI者的1年、3年和5年无活检升级生存率分别为98%、90%和83%,对照组分别为93%、75%和56%(所有p<0.01);Cox回归分析显示,招募时mpMRI±靶向活检与无活检升级生存率相关(HR 0.3;95%CI 0.2-0.6;p<0.01)。
关键数值与推荐
- 显著癌定义为Gleason评分≥4+3和/或pT≥3a和/或pN+。
- 无活检升级生存率定义为无升级或阳性针数≤3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究为单中心回顾性性质。
- 缺乏长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To understand the value of multiparametric magnetic resonance imaging (mpMRI) and targeted biopsies at recruitment on active surveillance (AS) outcomes. MATERIALS AND METHODS: This retrospective single-center study enrolled two cohorts of 206 and 310 patients in AS. The latter group was submitted to mpMRI and targeted biopsies at recruitment. Kaplan-meier curves quantified progression-free survival (PFS) and Bioptic-PFS (B-PFS: no upgrading or >3 positive cores) in the two cohorts. Cox-regression analyses tested independent predictors of PFS and B-PFS. In patients submitted to radical prostatectomy (RP) after AS, significant cancer (csPCa) was defined as: GS ≥ 4 + 3 and/or pT ≥ 3a and/or pN+ . Logistic-regression analyses predicted csPCa at RP. RESULTS AND LIMITATIONS: Median time follow-up and median time of persistence in AS were 46 (24-70) and 36 (23-58) months, respectively. Patients submitted to mpMRI at AS begin, showed greater PFS at 1- (98% vs. 91%), 3- (80% vs. 57%), and 5-years (70% vs. 35%) follow-up, respectively (all p < 0.01). At Cox-regression analysis only confirmatory mpMRI± targeted biopsy (HR: 0.3; 95% CI 0.2-0.5; p < 0.01) at AS begin was an independent predictor of PFS. Globally, 50 (16%) vs. 128 (62%) and 26 (8.5%) vs. 64 (31%) [all p < 0.01] men in the two groups experienced any-cause and bioptic AS discontinuation, respectively. Patients submitted to confirmatory mpMRI experienced greater 1-(98% vs. 93%), 3-(90% vs. 75%), and 5-years (83% vs. 56%) B-PFS, respectively (all p < 0.01). At Cox-regression analysis, mpMRI±-targeted biopsy at AS begin was associated with B-PFS (HR: 0.3; 95% CI 0.2-0.6; p < 0.01). No differences were recorded in csPCa rates between the two groups (22% vs. 28%; p = 0.47). Limitations of the study are the single-center retrospective nature and the absence of long-term follow-up. CONCLUSIONS: Confirmatory mpMRI±-targeted biopsies are associated with higher PFS and B-PFS during AS. However, a non-negligible percentage of patients experience csPCa after switching to active treatment.
引用
- Luzzago S, Catellani M, Di Trapani E, et al. Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. Prostate Cancer Prostatic Dis. 2019. PMID: 31249386. doi:10.1038/s41391-019-0160-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。